carboxyaminoimidazole ribotide (CAIR)

reacts with alanosine to form antimetabolite; substrate for EC 4.1.1.21; structure in second source

Also Known As:

CAIR; 5-amino-1-(5-O-phosphonopentofuranosyl)-1H-imidazole-4-carboxylic acid; 5-amino-4-imidazolecarboxylic acid ribonucleotide; AICOR; carboxy-AIR; 1H-Imidazole-4-carboxylic acid, 5-amino-1-(5-O-phosphono-beta-D-ribofuranosyl)-

Networked: 32 relevant articles (3 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Ribonucleotides: 307
    - carboxyaminoimidazole ribotide: 32

Experts

1.	Suwinski, Rafal: 7 articles (01/2016 - 10/2005)
2.	Jaworska, Magdalena: 4 articles (01/2016 - 06/2010)
3.	Skladowski, Krzysztof: 4 articles (03/2013 - 03/2003)
4.	Tarnawski, Rafal: 4 articles (03/2013 - 03/2003)
5.	Miszczyk, Leszek: 3 articles (01/2016 - 05/2008)
6.	Wozniak, Grzegorz: 3 articles (01/2016 - 05/2011)
7.	Maciejewski, Boguslaw: 3 articles (03/2013 - 10/2005)
8.	Brunschwiler, Thomas: 2 articles (02/2022 - 10/2020)
9.	Clarenbach, Christian F: 2 articles (02/2022 - 10/2020)
10.	Ivankay, Adam: 2 articles (02/2022 - 10/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "CAIR cures some mice bearing small (50 mm3) but not larger (100 mm3) 9464D-GD2 tumors and these cured mice develop weak memory responses against tumor rechallenge. " 06/01/2010 - "Tumor samples from 148 patients (72 p-CF and 76 p-CAIR patients) were available for molecular studies. " 01/01/2022 - "Treatment with CAIR cures 9464D-GD2 tumors in a NK cell dependent manner and induction of MHC-I by tumors cells was associated with decreased efficacy. " 01/01/2022 - "Early suppression of 9464D-GD2 tumors by CAIR does not require T or natural killer (NK) cells, but eventual tumor cures are NK cell dependent. " 01/01/2012 - "By contrast, tumors with low intensity of PTEN did not gain from p-CAIR (5-year LRC 56.2% vs. 47.2%, p = 0.49, RR = 0.94). "
2.	Oropharyngeal Neoplasms 05/01/2008 - "A statistically significant improvement in 3-year LRC in p-CAIR arm appeared in a subset of the patients with cancer of the oropharynx/oral cavity (74% p-CAIR vs. 53% CF, p=0.02). "
3.	Contracture 05/01/1989 - "Cl- -induced tension transients result from a primary component of Ca2+ release which triggers a secondary CaIR component; CaIR and caffeine contractures were eliminated by procaine. "
4.	Head and Neck Neoplasms (Head and Neck Cancer) 11/01/2006 - "To update 5-year results of a previously published study on special 7-days-a-week fractionation continuous accelerated irradiation (CAIR) for head-and-neck cancer patients. " 04/01/2001 - "[Randomized clinical trial on 7-day continuous accelerated irradiation (CAIR) of head and neck cancer. " 05/01/2000 - "Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity." 11/01/2006 - "Although this report is based on the relatively small group of patients, its results have encouraged us to use CAIR fractionation in a standard radiation treatment for moderately advanced head-and-neck cancer patients." 05/01/2011 - "Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer."
5.	Multiple Sclerosis 03/14/2017 - "Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)." 03/30/2011 - "Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)."

Related Drugs and Biologics

1.	Procaine (Novocaine)
2.	Caffeine (No Doz)
3.	Glatiramer Acetate (Copaxone)
4.	Cholinergic Agents (Cholinergics)
5.	Solutions
6.	Interleukin-2 (IL2)

Related Therapies and Procedures

1.	Radiotherapy
2.	Chemoradiotherapy
3.	Carotid Endarterectomy
4.	Therapeutics
5.	Immunotherapy